TickerTalks
Browse all tickers →
TickerTalks›$QURE
QUQURE

uniQure N.V.

Hot onWhy it's trendingX chatter spiked vs its recent normMoving on elevated volumeBacked by solid revenue growth
$QURE·$3.0B·Biotechnology·Healthcare
$46.29-3.9%YTD+92.6%1Y+206.6%
Mentions · last 7 days
2026-06-11: 91 posts2026-06-12: 100 posts2026-06-13: 107 posts2026-06-14: 117 posts2026-06-15: 148 posts2026-06-16: 157 posts2026-06-17: 904 posts1,634+122%
Price updated 11h ago·X counts updated 1d ago
QUQURE
uniQure N.V.$QURE
$46.29-3.88%1.6k posts+122%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $QURE, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-06-19

The move is getting stronger, with heavier trading behind it.

uniQure soared 78% on FDA accepting AMT-130 Phase 1/2 data as a basis for accelerated Huntington's approval — the BLA filing lands Q3 2026.

uniQure is a Netherlands-based gene therapy company centered on AMT-130, a one-time gene therapy for Huntington's disease — a currently-untreatable condition with no approved disease-modifying therapy. The June 17 news was transformative: following a Type B FDA meeting, the agency communicated that the 3-year Phase 1/2 analysis would be acceptable as the primary basis for an accelerated-approval BLA, with submission planned for Q3 2026. The stock soared 78% on the news, taking shares to $46.29 (up 93% YTD, 207% over twelve months). The standalone print is pure clinical-stage: Q1 26 revenue $3.6M (royalty/license income), operating margin -1,240%, cash burn ~$40M per quarter, but the pipeline now includes a high-probability accelerated approval path. Insider behavior is mixed — multiple directors sold ~$54K each on June 11 at $27 (pre-news), but director Balachandran sold $278K post-news on June 15 at $27.85. The bet is whether the Q3 2026 BLA filing converts cleanly to accelerated approval — a binary outcome that could double or halve the equity.

Agrees with X sentimentThe 'gene-therapy validation moment' framing is appropriate — FDA accepting Phase 1/2 data as primary basis for accelerated approval in Huntington's is a category-redefining regulatory signal. The 4+ years of patient follow-up showing maintenance of functioning is what makes the data unusual.

What to watch: Q3 2026 BLA filing (specific date pending) — the actual submission is the next catalyst, then FDA priority-review designation. Confirmatory study design alignment in the next 30 days (per the June 17 disclosure) is the immediate disclosure to watch.

On the calendar: 2026-08-04 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment37 posts analyzed · as of 2026-06-18

uniQure is rocketing on the FDA allowing the use of three-year Phase I/II AMT-130 data as the primary basis for an accelerated approval BLA filing planned for Q3 2026 in Huntington's disease. Bulls cite 4+ years of patient follow-up still showing patients who were working full-time still working, the new FDA framing of taking expert opinions into account, simultaneous regulatory filings being planned in the US and UK, and active hiring beginning to support both filings. ClearPoint CLPT is up 34 percent in sympathy. The dominant tone is the gene-therapy validation moment with the HD community deserving the win. Positioning chatter is conviction-heavy with bulls expecting another 9/24/25-style breakout and de-de-risking event.

Read the AI verdict + X sentiment for $QURE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm's most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its flagship program, uniQure is actively developing several other candidates. This includes AMT-130, a gene therapy undergoing Phase I/II clinical assessment for Huntington's disease, and AMT-060, also in Phase I/II clinical trials for hemophilia B. The company's pipeline further extends to AMT-210 for Parkinson's disease, AMT-260 aimed at temporal lobe epilepsy, and AMT-161, which addresses amyotrophic lateral sclerosis. Furthermore, AMT-240 is an early-stage, preclinical product candidate focused on autosomal dominant Alzheimer's disease. Established in 1998, uniQure N.V. maintains its corporate headquarters in Amsterdam, Netherlands.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $QURE.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

See how Biotechnology shapes $QURE

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $QURE's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IBBiShares Biotechnology ETF
+2.4%YTD
+38.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-14.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-26.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
167.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-146%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
74.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$-0.85$-0.88+3.4%
Q4 2025Mar 2, 2026$-0.56$-0.93+39.8%
Q3 2025Nov 10, 2025$-1.38$-0.85-62.4%
Q2 2025Jul 29, 2025$-0.69$-0.89+22.5%
Next earningsTue, Aug 4·consensus EPS $-0.88

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.6M+127.3%93.9%-1243%$-0.85$-38.4M
Q4 FY25$5.6M+6.6%38.8%-937%$-0.59$-77.2M
Q3 FY25$3.7M+61.8%89.2%-1379%$-1.38$-16.3M
Q2 FY25$5.3M-52.7%87.5%-834%$-0.69$-40.2M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$21.9M$16.0M – $32.7M-$3.51-$4.24 – -$3.189
FY27$75.9M$62.9M – $88.9M-$3.05-$3.07 – -$3.046
FY28$184.0M$145.6M – $237.4M-$2.46-$4.39 – $1.377
FY29$312.4M$247.2M – $403.0M-$1.10-$1.51 – -$0.803
FY30$498.2M$394.1M – $642.6M$0.54$0.40 – $0.756

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.60%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+91.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+68.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 53.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today9.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.005-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Know if $QURE is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 15Madhavan BalachandranDirector10.0K sh$279KSellJun 15Jeannette PottsChief Legal Officer5.2K sh$145KSellJun 11Robert GutDirector2.7K sh$74KSellJun 11Kylie O'keefeChief Customer & Strat Officer15.9K sh$431KSellJun 11Jeremy P. SpringhornDirector2.0K sh$54KSellJun 11Leonard E PostDirector2.0K sh$54KSellJun 11David D. MeekDirector2.0K sh$54KSellJun 11Jack KayeDirector2.0K sh$54KSellJun 11Jacques Rachelle SuzanneDirector2.0K sh$54KSellJun 11Madhavan BalachandranDirector2.0K sh$54K
1–10 of 16
+ 15 other (11 awards · 4 exempts) in window

See when $QURE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJun 158-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

uniQure N.V. filed an 8-K (Items 5.02, 5.03, 5.07) dated June 10, 2026, reporting officer/director changes, an amendment to articles of incorporation or bylaws, and shareholder vote results from its annual meeting. The excerpt is cover-page only with no specifics on which directors/officers changed or what bylaw amendment was approved. The combination of governance changes and a charter amendment may reflect board refreshment or structural changes relevant to uniQure's clinical-stage gene therapy programs.

8-KPress release / Reg FDApr 308-K — Item 7.01: Press release / Reg FD
AI summary

uniQure N.V. filed an 8-K under Item 7.01 (Reg FD) on April 30, 2026, furnishing an investor presentation for this Netherlands-based gene therapy company. The excerpt is XBRL boilerplate with no topic or slide content visible. Routine Reg FD disclosure — for a clinical-stage biotech like uniQure, investor presentations often include pipeline updates and clinical data readouts, making the attached exhibit potentially relevant for AMT-130 (Huntington's) development timeline watchers.

3New insider — initial holdingsMar 93
8-KPress release / Reg FDMar 28-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDJan 138-K — Item 7.01: Press release / Reg FD
8-KPress release / Reg FDJan 98-K — Item 7.01: Press release / Reg FD
+ 18 other (10 13Gs · 2 proxys · 1 routine 8-K · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

UniQure: AMT-130's FDA Path Reaffirms My Bull Caseseekingalpha.com·23h agouniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?zacks.com·1d agouniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaringseekingalpha.com·2d agoBiotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An Endinvestors.com·2d agoUniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agencycnbc.com·2d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$ALT$IBRX$RXRX$REPL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport